Everolimus causes side effects in the majority of people who take it, with mouth sores, fatigue, infections, blood count changes, elevated blood sugar, and rashes ranking among the most common. About two-thirds of patients on the drug develop some degree of oral inflammation, and roughly one in eight will stop treatment because of side effects overall. The drug is used across a wide range of conditions, from advanced cancers to transplant rejection to tuberous sclerosis complex, and the side-effect profile shifts somewhat depending on the dose, the disease being treated, and what other medications are on board.
Mouth Sores Are the Most Common Problem
The side effect that drives the most day-to-day misery for people on everolimus is stomatitis, a painful inflammation of the mouth lining. A meta-analysis across multiple solid-tumor and tuberous sclerosis complex trials found that roughly 67–70% of patients developed some degree of stomatitis, though most cases were mild to moderate; only about 8–9% of patients experienced severe (grade 3 or 4) mouth sores.1Annals of Oncology. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy The ulcers are distinctive. They tend to be large, shallow, and solitary or few in number, appearing almost exclusively on the softer surfaces inside the mouth rather than the gums or hard palate. They can show up within the first couple of weeks of starting treatment or crop up months later.2PubMed. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus
These ulcers look different from the scattered, tiny sores caused by conventional chemotherapy or from cold sores caused by herpes virus. The distinction matters clinically because the treatment approach differs. For everolimus-related mouth sores, swishing and spitting a steroid-based mouthwash has become common practice, but the evidence behind this strategy is more complicated than it initially looked.
The Mouthwash Debate
A single-arm trial called SWISH tested prophylactic dexamethasone mouthwash in women receiving everolimus plus exemestane for breast cancer. The results were striking: only about 2% of patients developed grade 2 or worse stomatitis by eight weeks, compared with a historical rate of 33% from an earlier trial.3The Lancet Oncology. Everolimus plus exemestane with prophylactic dexamethasone mouthwash to reduce stomatitis in women with hormone receptor-positive, HER2-negative advanced breast cancer (SWISH) That trial made dexamethasone mouthwash a widely recommended preventive step.
But a follow-up randomized trial, the Alliance MIST study, compared starting the dexamethasone mouthwash right away (prophylactically) versus waiting and only using it once mouth pain began (therapeutically). The trial found no significant difference between the two approaches in either the rate of mouth sores or the amount of pain patients experienced.4PubMed Central. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701) That study was limited by poor enrollment, so the question is not fully settled. In practice, many oncologists still recommend starting the mouthwash from day one, since dexamethasone mouthwash is cheap and low-risk. But you should know that waiting until the first twinge of discomfort and then starting the rinse may work just as well.
Metabolic Disruptions
Everolimus can push blood sugar upward even in people who have never had diabetes. A meta-analysis of cancer trials found the drug roughly tripled the risk of high-grade hyperglycemia compared to placebo, with the overall rate of elevated blood sugar attributable to everolimus sitting around 7% across all grades.5PubMed. Risk of hyperglycemia attributable to everolimus in cancer patients: A meta-analysis The effect varies by cancer type: people with kidney cancer seem most susceptible, with rates above a quarter, while breast cancer patients see a much lower incidence.
Research into the mechanism suggests everolimus impairs the pancreas’s ability to secrete insulin rather than making tissues resistant to it. In a detailed study of individual patients, investigators found that insulin sensitivity in the liver, muscles, and fat tissue remained normal, but insulin secretion dropped, leading the liver to release more glucose than it should. The good news is the hyperglycemia appears fully reversible once the drug is stopped; none of the patients in that study needed ongoing diabetes medication after discontinuing everolimus.6PubMed. The clinical course and potential underlying mechanisms of everolimus-induced hyperglycemia While on the drug, though, most patients who develop significant blood sugar elevations need insulin or medications that stimulate insulin release to stay in a safe range.
Blood lipids can also spike. Triglycerides, in particular, can climb to dangerous levels in rare cases. One heart transplant recipient saw triglyceride levels shoot above 5,000 mg/dL (normal is under about 177) roughly eleven weeks after starting everolimus. The levels came back down after the drug was stopped and aggressive treatment was given.7PubMed Central. Severe hypertriglyceridemia associated with everolimus treatment after heart transplantation This extreme scenario is uncommon, but moderate cholesterol and triglyceride increases are frequently seen and often need to be managed with statins or other lipid-lowering drugs alongside regular lab monitoring.
Blood Count Changes
Everolimus suppresses the bone marrow to a degree that shows up on routine blood tests. A systematic review and meta-analysis across solid tumor trials found these approximate rates of blood count changes:
- Anemia: about 61% of patients (severe in roughly 8%)
- Lymphopenia: about 41% (severe in roughly 15%)
- Thrombocytopenia: about 36% (severe in roughly 5%)
- Neutropenia: about 22% (severe in roughly 4%)
Compared to placebo, the drug carries several-fold higher risk of low platelets, low lymphocyte counts, and anemia.8PubMed. Risk of hematologic toxicities in patients with solid tumors treated with everolimus: a systematic review and meta-analysis In a smaller study focused specifically on metastatic breast cancer patients, anemia appeared in about 71% and thrombocytopenia in about 55%, though most cases were mild enough that they did not require changing the dose.9PubMed. Everolimus-induced hematologic changes in patients with metastatic breast cancer The practical implication is that regular blood count checks are a non-negotiable part of being on everolimus. Fatigue from the drug often has low red blood cell counts hiding behind it.
Lung Inflammation
One of the more concerning side effects is noninfectious pneumonitis, an inflammation of the lungs not caused by any germ. In a study of patients with advanced kidney cancer, clinical pneumonitis was suspected in about 14% of those on everolimus, with none seen in the placebo group. Most cases were mild or moderate, but roughly 4% had symptoms that interfered with daily life or required supplemental oxygen. No life-threatening cases occurred in that study. Over half of the cases resolved during follow-up, either after the dose was reduced or the drug was stopped, and steroid treatment was used in about half the affected patients.10American Journal of Respiratory and Critical Care Medicine. Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma
Case reports from transplant recipients illustrate what the more severe end of the spectrum looks like. In one case, a lung transplant patient developed progressive shortness of breath and required supplemental oxygen six months after starting everolimus. A lung biopsy confirmed the diagnosis, and after the drug was stopped and steroids were given, the patient’s imaging cleared completely within four weeks.11PubMed Central. Everolimus-Induced Pulmonary Toxicity in a Lung Transplant Recipient: A Case Report Another transplant recipient followed a similar trajectory: lung infiltrates on imaging, exclusion of infection, and full resolution of the changes on follow-up CT after switching to a different immunosuppressant.12PubMed Central. Everolimus induced pneumonitis in a lung transplant recipient The challenge is distinguishing drug-induced pneumonitis from an infection, because the symptoms overlap. Any new cough, shortness of breath, or unexplained lung changes on imaging while on everolimus should prompt a workup.
Skin Rash
About 29% of patients on everolimus develop a rash of some kind, based on a meta-analysis of clinical trials. That is nearly four times the rate seen in people on placebo. The encouraging piece is that severe rash is rare, occurring in about 1% of patients, and the increase in risk for severe rash was not statistically significant compared to placebo.13PubMed Central. Rash to the mTOR inhibitor everolimus: systematic review and meta-analysis The rash typically appears as an acne-like eruption or a more generalized dry, flaky skin reaction. It is more of a nuisance than a danger for most people, but it can affect quality of life, especially when it appears on the face.
Infection Risk and Hepatitis B Reactivation
Because everolimus suppresses the immune system, infections are a real and sometimes serious concern. A real-world study of patients with neuroendocrine tumors treated with everolimus found that about 31% developed infections of any grade over a median follow-up of nearly three years. About 22% had a serious infection, and roughly 6% developed an opportunistic infection, the kind caused by organisms that usually only cause trouble when the immune system is weakened, including Candida, Pneumocystis, Herpes, and Cryptococcus species. Four patients in that cohort died from infections, though only two of those deaths were judged to be everolimus-related. Longer duration on the drug was an independent risk factor for serious infection.14Neuroendocrinology. Opportunistic and Serious Infections in Patients with Neuroendocrine Tumors Treated with Everolimus: A Multicenter Study of Real-World Patients
One infection risk that deserves special attention is hepatitis B virus reactivation. A study focusing on patients in regions where hepatitis B is common found that among those who were carriers (HBsAg-positive), the reactivation rate was about 6% in patients who received preventive antiviral therapy and about 11% in those who did not. Some of these reactivations led to severe hepatitis, and two patients died. Even patients who had cleared the virus in the past but still carried antibodies against it (anti-HBc positive) could reactivate, and two such patients developed severe hepatitis as well.15PubMed Central. Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas Screening for hepatitis B before starting everolimus and using preventive antiviral treatment for carriers are standard precautions.
Wound Healing and Surgical Timing
If you need surgery while on everolimus, wound healing is a legitimate concern. Animal studies have shown that everolimus reduces wound strength in a dose-dependent manner when given on the day of surgery, though delaying the start of the drug after the operation can mitigate this effect.16PubMed. Everolimus-induced loss of wound strength can be prevented by a short postoperative delay in its administration In kidney transplant recipients, everolimus-based regimens have been associated with a higher proportion of wound healing complications compared to mycophenolate-based regimens.17PubMed Central. Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus
Interestingly, a study in heart transplant patients who were started on everolimus early with withdrawal of cyclosporine did not show a statistically significant difference in wound complications or total surgical events compared to a cyclosporine-based group.18PubMed. Wound complications and surgical events in de novo heart transplant patients treated with everolimus: Post-hoc analysis of the SCHEDULE trial The picture is not entirely consistent across organ types, and the background immunosuppressive regimen matters. In practice, most surgical teams prefer to pause or reduce everolimus before elective procedures and restart it once healing is underway.
How Other Drugs Change the Side-Effect Picture
Everolimus is metabolized by the same liver enzyme pathway that processes many other drugs, and the combinations matter enormously. Cyclosporine, another immunosuppressant commonly used in transplant recipients, dramatically increases everolimus blood levels. In one comparison, the same fixed dose of everolimus produced blood concentrations about 2.5 times higher when given alongside cyclosporine compared to tacrolimus.19PubMed. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus Animal studies have confirmed this interaction: increasing cyclosporine doses cause progressively higher everolimus concentrations in both the blood and kidney tissue.20PLoS ONE. Everolimus and Sirolimus in Combination with Cyclosporine Have Different Effects on Renal Metabolism in the Rat Higher everolimus levels mean more side effects, so transplant teams adjust doses carefully when these drugs are used together.
This interaction is not unique to cyclosporine. Strong inhibitors of the CYP3A4 enzyme (certain antifungals, some antibiotics, grapefruit juice in large quantities) can boost everolimus levels, while inducers (some seizure medications, rifampin) can lower them. Any new medication started during everolimus therapy warrants a conversation with the prescribing physician about potential interactions.
When Patients Stop Treatment
About 12% of cancer patients on everolimus end up discontinuing the drug because of adverse events, compared with about 5% on placebo, giving a relative risk of roughly 2.6.21PubMed. Discontinuation of Everolimus Due to Related and Unrelated Adverse Events in Cancer Patients: A Meta-Analysis In the large BOLERO-2 breast cancer trial, the discontinuation rate due to adverse events was 9% with everolimus plus exemestane versus 3% with placebo plus exemestane. Dose reductions and temporary interruptions were far more common than permanent discontinuation, with a median interruption duration of about seven days.22PubMed Central. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 Many side effects are manageable with dose adjustments and supportive care, and stopping entirely is a last resort for most patients.
Drug Levels Matter More Than the Dose on the Pill Bottle
One of the more underappreciated aspects of everolimus side effects is that the standard flat dose given to cancer patients (typically 10 mg daily) produces wildly different blood concentrations from person to person. A prospective study in neuroendocrine tumor patients found that blood trough concentrations of 6 ng/mL or higher were associated with increased toxicity, whereas the nominal pill dose alone was not a reliable predictor of adverse events.23PubMed Central. The relationship between dose, concentration and toxicity of everolimus in the treatment of neuroendocrine tumors: A prospective observational study In the transplant world, therapeutic drug monitoring is already standard, with a recommended trough concentration of 3 to 8 ng/mL. Concentrations above 8 ng/mL have been associated with increased toxicity, while levels below 3 ng/mL are tied to a higher chance of organ rejection.24PubMed. The role of therapeutic monitoring of everolimus in solid organ transplantation
For cancer patients, therapeutic drug monitoring is not yet standard practice, but there is growing interest in adopting it. The logic is simple: if two people take the same 10 mg pill but one ends up with a trough level of 4 ng/mL and the other hits 16 ng/mL, they are effectively on very different treatments. Adjusting the dose based on blood levels rather than body weight or a flat number could spare some patients unnecessary toxicity while ensuring others are getting enough drug to benefit.25PubMed. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship This is an area where the science has not caught up with the clinical need, and dosing for oncology indications has been described as having room for improvement.26PubMed Central. A pharmacological rationale for improved everolimus dosing in oncology and transplant patients
Side Effects in Children and Adolescents
Everolimus is used in younger patients primarily for tuberous sclerosis complex, either to shrink brain tumors (subependymal giant cell astrocytomas) or to control seizures. In a small study of children treated for tuberous sclerosis, the drug was described as well tolerated, with mild stomatitis, lipid elevations, and constipation being the main reported issues. None of the adverse effects were severe enough to require stopping or reducing the dose.27PubMed. Beneficial Effects of Everolimus on Autism and Attention-Deficit/Hyperactivity Disorder Symptoms in a Group of Patients with Tuberous Sclerosis Complex
Longer-term data from the open-label extension of the EXIST-3 seizure trial paint a slightly more complex picture. Severe adverse events (grade 3 or 4) occurred in 45% of younger patients and 38% of older patients, with pneumonia being the most common serious event in both groups. Two deaths occurred during the extension phase, one from pneumonia suspected to be treatment-related. Despite those numbers, the investigators concluded the drug was well tolerated overall, reflecting how the risk-benefit calculus shifts when the alternative is uncontrolled seizures.28The Lancet Child & Adolescent Health. Efficacy and safety of adjunctive everolimus in patients with tuberous sclerosis complex-associated seizures (EXIST-3) Parents should be aware that infection monitoring in children on everolimus is especially important, and that the side-effect profile broadly mirrors what is seen in adults but with pneumonia being a particularly notable concern.
Genetic Factors That May Predict Who Gets Hit Hardest
Not everyone reacts the same way, and researchers have begun looking at whether genetic variations can predict who will develop specific side effects. A study of metastatic breast cancer patients on everolimus found several genetic markers linked to particular toxicities. Patients carrying a certain variant of the ABCB1 gene had about twice the risk of developing mouth sores. A variant in the RAPTOR gene was associated with a lower risk of pneumonitis. And a variant in the PIK3R1 gene was associated with a reduced risk of high blood sugar but, paradoxically, a much higher risk of low white blood cell counts.29PLoS ONE. Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer None of these markers are used in routine clinical decision-making yet, but they point toward a future where a blood test before starting treatment could flag patients most likely to need aggressive supportive care or closer monitoring for specific complications.
Effects on Fertility
Animal studies have raised flags about everolimus and male fertility. In mice, the drug reduced sperm counts by roughly 65–77%, comparable to the reduction seen with its closely related cousin sirolimus. The effect was reversible: after the drug was stopped, males were able to father litters. Even at the higher dose, treated males eventually produced offspring, though sperm counts at certain doses remained statistically lower than controls during the treatment period.30Oxford Academic (Biology of Reproduction). The rapamycin analog Everolimus reversibly impairs male germ cell differentiation and fertility in the mouse Human data on this point are limited, but the animal findings are strong enough that fertility preservation should be discussed with patients of reproductive age before starting long-term everolimus therapy, particularly men. The reversibility is reassuring but not a guarantee that the same timeline applies in humans.